Jump to navigation
About
Mission and Values
Leadership Team
Board of Directors
Medical Advisors
Focus
Hyperoxaluria
Systemic Oxalosis
Hyperuricemia
Publications
Products
Reloxaliase
ALLN-346
Pipeline
FAQs
Investors
Overview
News Releases
Events and Presentations
Stock Information
Analyst Coverage
Corporate Governance
SEC Filings
Shareholder Services
Careers
Contact
Home
Dedicated to Treating Patients
With Rare and Severe
Metabolic Diseases
Utilizing the GI Tract
to Reduce the Burden
of Metabolic Disease
Understanding
Metabolic Diseases
that Affect the Kidney
News
January 4, 2019
Allena Pharmaceuticals Announces Appointment of Louis Brenner, M.D. as Chief Executive Officer and Confirms Key Milestones for 2019
Read more
about Allena Pharmaceuticals Announces Appointment of Louis Brenner, M.D. as Chief Executive Officer and Confirms Key Milestones for 2019
January 2, 2019
Allena Pharmaceuticals Achieves Alignment with FDA on Phase 3 Program and Accelerated Approval Pathway for Reloxaliase in Enteric Hyperoxaluria
Read more
about Allena Pharmaceuticals Achieves Alignment with FDA on Phase 3 Program and Accelerated Approval Pathway for Reloxaliase in Enteric Hyperoxaluria
November 7, 2018
Allena Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update
Read more
about Allena Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update
